NZ566117A - Oral suspension of prednisolone acetate - Google Patents

Oral suspension of prednisolone acetate

Info

Publication number
NZ566117A
NZ566117A NZ566117A NZ56611706A NZ566117A NZ 566117 A NZ566117 A NZ 566117A NZ 566117 A NZ566117 A NZ 566117A NZ 56611706 A NZ56611706 A NZ 56611706A NZ 566117 A NZ566117 A NZ 566117A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
composition
prednisolone
prednisolone acetate
suspension
Prior art date
Application number
NZ566117A
Other languages
English (en)
Inventor
Satish Asotra
Shen Gao
Avraham Yacobi
Original Assignee
Taro Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceuticals North America Inc filed Critical Taro Pharmaceuticals North America Inc
Publication of NZ566117A publication Critical patent/NZ566117A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ566117A 2005-08-04 2006-08-03 Oral suspension of prednisolone acetate NZ566117A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70537005P 2005-08-04 2005-08-04
PCT/US2006/030140 WO2007019184A2 (en) 2005-08-04 2006-08-03 Oral suspension of prednisolone acetate

Publications (1)

Publication Number Publication Date
NZ566117A true NZ566117A (en) 2011-06-30

Family

ID=37727875

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ566117A NZ566117A (en) 2005-08-04 2006-08-03 Oral suspension of prednisolone acetate

Country Status (11)

Country Link
US (4) US7799331B2 (https=)
EP (2) EP2630951A1 (https=)
JP (2) JP2009503097A (https=)
KR (1) KR20080044245A (https=)
CN (1) CN101247786A (https=)
AU (1) AU2006278620B2 (https=)
CA (1) CA2616112A1 (https=)
IL (1) IL189257A0 (https=)
NZ (1) NZ566117A (https=)
WO (1) WO2007019184A2 (https=)
ZA (1) ZA200800926B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2001442A4 (en) * 2006-04-06 2013-10-23 Taro Pharmaceuticals North America Inc NOVEL EXPERIMENTAL FORMULATIONS WITH HYDROCOLLOIDAL POLYMERS
EP2197416A1 (en) * 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
ES2811051T3 (es) * 2008-08-20 2021-03-10 Univ California Corticosteroides para el tratamiento de enfermedades inflamatorias del tracto gastrointestinal
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
JP6694525B2 (ja) * 2016-05-06 2020-05-13 ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． 薬学的眼病用組成物およびそれを製造するための方法
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265823A (en) * 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4448774A (en) 1982-12-22 1984-05-15 Fisons Corporation Steroid formulation
US5145675A (en) * 1986-03-31 1992-09-08 Advanced Polymer Systems, Inc. Two step method for preparation of controlled release formulations
CA2138957A1 (en) * 1992-07-30 1994-02-17 Shigeki Omura A remedy for inflammatory intestinal diseases
IL108366A (en) 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002058662A2 (en) * 2001-01-24 2002-08-01 Oraceutical Llc Topical oral care compositions
ATE502642T1 (de) 2001-10-05 2011-04-15 Zalicus Inc Kombinationen für die behandlung von immun- entzündlichen erkrankungen
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
AU2003238221A1 (en) 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
EP1658083B1 (en) * 2003-06-19 2007-08-08 BODOR, Nicholas S. Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
CA2550811C (en) 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
EP1744760B1 (en) * 2004-04-22 2015-01-07 AcuCort AB Pharmaceutical compositions for acute glucocorticoid therapy
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate

Also Published As

Publication number Publication date
US8206727B2 (en) 2012-06-26
WO2007019184A3 (en) 2007-09-20
AU2006278620B2 (en) 2012-02-02
WO2007019184A2 (en) 2007-02-15
AU2006278620A1 (en) 2007-02-15
KR20080044245A (ko) 2008-05-20
US20120238534A1 (en) 2012-09-20
US20100324007A1 (en) 2010-12-23
EP2630951A1 (en) 2013-08-28
IL189257A0 (en) 2008-08-07
ZA200800926B (en) 2012-04-24
US20130143853A1 (en) 2013-06-06
US7799331B2 (en) 2010-09-21
US8461139B2 (en) 2013-06-11
JP2013014634A (ja) 2013-01-24
EP1909798A2 (en) 2008-04-16
CN101247786A (zh) 2008-08-20
JP2009503097A (ja) 2009-01-29
CA2616112A1 (en) 2007-02-15
EP1909798A4 (en) 2010-10-27
US20070031459A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
US8461139B2 (en) Oral suspension of prednisolone acetate
JP6092629B2 (ja) リファキシミン使用準備済懸濁液
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
AU2015305510A1 (en) Natural suspending agent including a synergistic blend of Xanthan gum and Konjac powder for oral pharmaceutical suspensions
WO2013024373A1 (en) Pharmaceutical composition comprising cefuroxime
US20250127714A1 (en) Oral composition of celecoxib for treatment of pain
CN108430469A (zh) St-246(特考韦瑞一水合物)混悬制剂
EP3644968B1 (en) Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability
JPH07126154A (ja) 難水溶性医薬品含有医薬製剤
JP7804698B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
EP1572158A1 (en) A new oral immediated release dosage form
US20090060995A1 (en) Dispersible sustained release pharmaceutical compositions
EP4694865A1 (en) Liquid composition of phosphodiesterase type 5 (pde-5) inhibitors, a method of preparation thereof and the use thereof for the treatment of erectile dysfunctions
EA052489B1 (ru) Жидкая композиция ингибиторов фосфодиэстеразы типа 5 (pde-5), способ ее получения и ее применение для лечения эректильных дисфункций
EA041538B1 (ru) Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью
Sushma et al. Available online through

Legal Events

Date Code Title Description
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: CORRECTION TO FILING DATE (22)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 AUG 2016 BY DENNEMEYER + CO

Effective date: 20130725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20160719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20170801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2019 BY COMPUTER PACKAGES INC

Effective date: 20180718

ASS Change of ownership

Owner name: TARO PHARMACEUTICALS INC., CA

Effective date: 20190527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2020 BY COMPUTER PACKAGES INC

Effective date: 20190731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2021 BY COMPUTER PACKAGES INC

Effective date: 20200818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2022 BY COMPUTER PACKAGES INC

Effective date: 20210917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2023 BY COMPUTER PACKAGES INC

Effective date: 20220717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2024 BY COMPUTER PACKAGES INC

Effective date: 20230730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 AUG 2025 BY COMPUTER PACKAGES INC

Effective date: 20240730

LAPS Patent lapsed